Ferring looks to gain microbiome drug approval with Rebiotix buy

By Staff Reporter

- Last updated on GMT

GettyImages/ChrisChrisW
GettyImages/ChrisChrisW
Ferring Pharmaceuticals is buying Rebiotix and says its lead candidate has the potential to be the first human microbiome product approved anywhere in the world.

The proposed acquisition – financials of which have not been divulged – will see Swiss pharma firm Ferring add Rebiotix’ Microbiota Restoration Therapy (MRT) drug platform, along with the lead product RBX2660, a non-antibiotic treatment in Phase III development for the prevention of recurrent Clostridium difficile infection (CDI).

According to the firm, RBX2660 – which has received US Food and Drug Administration (FDA) Fast Track, Breakthrough Therapy and Orphan Drug Designations – has the potential to become the first human microbiome product approved anywhere in the world.

Therapies targeted towards the microbiome have the potential to transform healthcare,” ​said Ferring’s CFO Michel Pettigrew.

Rebiotix’ MRT drug platform offers a stable way of manufacturing and delivering healthy, live, human-derived microbes into the gastrointestinal tract, the firm says.

Abnormalities in the human gut microbiota have been implicated in many diseases. In addition to C. diff.​, researchers worldwide are investigating possible links between the gut microbiota and other infectious, metabolic, liver, inflammatory, and neurological diseases.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more